Ophthalmology in the Covid-19 Era: 4 Part Series
While the COVID-19 pandemic has dramatically changed health care delivery in the US, patients with vision diseases in need of intravitreal anti-VEGF therapy must adhere to their treatment schedules or risk vision deterioration or loss. This includes patients with diabetic retinopathy (DR), diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), and retinal vein occlusion (RVO). As therapies for these disorders continue to make incremental improvements to minimize treatment burden and improve outcomes, clinicians who provide anti-VEGF therapy need to be kept up to date with the latest data and best practices.